Enlivex Therapeutics Ltd Stock Price, News & Analysis

Enlivex (Nasdaq and TASE: ENLV) announced the closing of a $212,000,000 private placement on November 26, 2025. The company said it will use net proceeds to implement the world’s first RAIN prediction markets token digital-asset treasury strategy while continuing core operations.

RAIN is described as a decentralized predictions and options protocol on Arbitrum with AI-resolved outcomes and a deflationary Buyback & Burn governance token. The company also appointed Matteo Renzi, former Italian prime minister, to its board of directors. BTIG served as sole placement agent.

Enlivex (NASDAQ: ENLV) announced a $212,000,000 private placement of 212,000,000 ordinary shares at $1.00 per share (an 11.5% premium to the Nov 21, 2025 close), funded in a combination of USD and USDT, with proceeds intended to implement a RAIN prediction‑markets token treasury strategy while continuing core clinical work. The company also announced the appointment of Matteo Renzi, former prime minister of Italy, to the Enlivex board effective November 24, 2025. RAIN is described as a decentralized prediction and options protocol on the Arbitrum network with AI‑resolved markets and a buyback & burn token mechanism.

Enlivex (Nasdaq: ENLV) announced a $212,000,000 PIPE to sell 212,000,000 shares at $1.00 per share (an 11.5% premium to the Nov 21, 2025 close), funded in a combination of USD and USDT.

Proceeds are intended to implement the first RAIN prediction markets token treasury strategy via RAIN token accumulation while the company continues clinical development of Allocetra for knee osteoarthritis. Former Italian prime minister Matteo Renzi will join the board following closing. The closing is expected on or before November 25, 2025, subject to customary conditions. BTIG is sole placement agent.

Enlivex (Nasdaq: ENLV) announced positive six-month topline Phase IIa data for Allocetra in patients with age-related primary moderate-to-severe knee osteoarthritis.

Key findings: durable pain and function improvement versus placebo in the 60+ population (3-month composite: -26.8 vs -13.4, p=0.008; 6-month composite at 61+: -27.8 vs -15.5, p=0.02). The company reported a favorable safety profile through six months and plans a Phase IIb trial to start in H1 2026.

Enlivex Therapeutics (Nasdaq: ENLV) will present Phase IIa 3-month topline data for Allocetra in moderate-to-severe knee osteoarthritis (KOA) at ACR Convergence 2025 on October 28, 2025.

The late-breaking poster reports clinically meaningful and statistically significant pain reduction and function improvement versus placebo in idiopathic age-related KOA patients (≥60 years), who represent >50% of the KOA market and 54% of the study population, and includes new supporting biomarker data.

Poster title: Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial (NCT06233474). Presentation by Prof. Philip Conaghan; Einat Galamidi, MD, CMO, available for meetings.

Enlivex Therapeutics (Nasdaq: ENLV) has announced an upcoming KOL webinar hosted by D. Boral Capital on September 30, 2025, at 10:00 AM ET. The webinar will focus on the company's knee osteoarthritis program and recent positive Phase IIa topline data from its Allocetra™ treatment.

The panel features distinguished experts including Professor Ali Mobasheri, Professor Philip Conaghan, Enlivex's Vice Chairman Dr. Roger Pomerantz, and D. Boral's Jason Kolbert. The data demonstrated significant improvements in pain reduction and function for moderate-to-severe knee osteoarthritis patients, addressing an unmet medical need in a large patient population with no currently approved disease-modifying therapies.

Enlivex Therapeutics (NASDAQ:ENLV) released a shareholder letter highlighting significant Phase IIa results for Allocetra™ in knee osteoarthritis (KOA) treatment. The trial demonstrated 72% pain reduction versus placebo and 109% function improvement in primary idiopathic age-related osteoarthritis patients aged 60 and above.

The treatment showed particularly strong results in older patients, with efficacy exceeding FDA thresholds for Phase III trials. Allocetra™ was well-tolerated with no drug-related serious adverse events. The company plans to release six-month data in November 2025 and initiate a Phase IIb trial in Q2 2026, focusing on primary KOA patients.

The potential market is significant, with over 32 million Americans affected by KOA, projected to reach 78 million by 2040. Enlivex is pursuing partnership opportunities with larger companies and non-dilutive funding options.

Enlivex Therapeutics (NASDAQ:ENLV) has secured an Israeli patent (No. 290470) for using Allocetra™ to treat osteoarthritis patients, extending protection through 2040. The company recently reported promising Phase IIa results showing significant improvements in knee osteoarthritis patients, including:

• 24% reduction in knee pain and 26% improvement in knee function in the overall modified intention-to-treat population
• 72% reduction in knee pain and 109% improvement in knee function in age-related primary osteoarthritis patients versus placebo

These results demonstrate clinically meaningful and statistically significant effects in common Phase III primary endpoints for knee osteoarthritis trials.

Enlivex Therapeutics (NASDAQ:ENLV) announced positive three-month topline data from its Phase I/II trial of Allocetra™ for moderate-to-severe knee osteoarthritis. The trial demonstrated significant improvements across all efficacy endpoints, with the treatment arm showing a 24% reduction in knee pain and 26% improvement in knee function versus placebo.

Notably, in age-related primary osteoarthritis patients, the results were even more impressive, showing a 72% reduction in knee pain and 95% improvement in knee function compared to placebo - achieving statistically significant effects in common Phase III primary endpoints. The treatment demonstrated a favorable safety profile with no severe adverse events, showing only mild to moderate, transient, and treatable side effects.